Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) has a beta value of 1.3 and has seen 2,173,544 shares traded in the last trading session. The company, currently valued at $505.63 Million, closed the last trade at $4.87 per share which meant it gained $0.29 on the day or 6.33% during that session. The CPRX stock price is -6.57% off its 52-week high price of $5.19 and 40.86% above the 52-week low of $2.88. If we look at the company’s 10-day average daily trading volume, we find that it stood at 958.36 Million shares traded. The 3-month trading volume is 1.53 Million shares.
The consensus among analysts is that Catalyst Pharmaceuticals Inc. (CPRX) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.09.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) trade information
Sporting 6.33% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, May 03 when the CPRX stock price touched $4.90-0 or saw a rise of 0.61%. Year-to-date, Catalyst Pharmaceuticals Inc. shares have moved 45.81%, while the 5-day performance has seen it change 5.64%. Over the past 30 days, the shares of Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) have changed 7.98%. Short interest in the company has seen 11.71 Million shares shorted with days to cover at 7.65.
Wall Street analysts have a consensus price target for the stock at $7.5, which means that the shares’ value could jump 54% from current levels. The projected low price target is $5.5 while the price target rests at a high of $9. In that case, then, we find that the current price level is +84.8% off the targeted high while a plunge would see the stock lose 12.94% from current levels.
Catalyst Pharmaceuticals Inc. (CPRX) estimates and forecasts
4 analysts offering their estimates for the company have set an average revenue estimate of $32.1 Million for the current quarter. 4 have an estimated revenue figure of $32.7 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $29.14 Million for this quarter, and analysts expect sales will grow by 10.2% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +37% over the past 5 years. Earnings growth for 2021 is a modest +134.7%.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX)’s Major holders
Insiders own 6.97% of the company shares, while shares held by institutions stand at 64.34% with a share float percentage of 69.16%. Investors are also buoyed by the number of investors in a company, with Catalyst Pharmaceuticals Inc. having a total of 202 institutions that hold shares in the company. The top two institutional holders are Armistice Capital, LLC with over 10Million shares worth more than $33.4 Million. As of December 30, 2020, Armistice Capital, LLC held 9.63% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 7.74 Million shares as of December 30, 2020. The firm’s total holdings are worth over $25.87 Million and represent 7.46% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of March 30, 2021, the former fund manager holds about 6.19% shares in the company for having 6429429 shares of worth $29.64 Million while later fund manager owns 3.3 Million shares of worth $11.01 Million as of December 30, 2020, which makes it owner of about 3.17% of company’s outstanding stock.